Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.
Industry, Sector and Symbol:
Capitalization:- Market Cap: $154.38 million
- Outstanding Shares: 75,309,000
Average Prices:- 50 Day Moving Avg: $1.88
- 200 Day Moving Avg: $3.26
- 52 Week Range: $1.50 - $8.35
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.73
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $12.04 million
- Price / Sales: 12.82
- Book Value: $1.33 per share
- Price / Book: 1.54
Profitability:- EBIDTA: ($67,940,000.00)
- Net Margins: -593.94%
- Return on Equity: -84.07%
- Return on Assets: -21.75%
Debt:- Debt-to-Equity Ratio: 0.42%
- Current Ratio: 0.59%
- Quick Ratio: 0.59%
Misc:- Average Volume: 1.05 million shs.
- Beta: 1.55
- Short Ratio: 2.11
Frequently Asked Questions for Sorrento Therapeutics (NASDAQ:SRNE)
What is Sorrento Therapeutics' stock symbol?
Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."
How were Sorrento Therapeutics' earnings last quarter?
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) announced its earnings results on Monday, November, 16th. The company reported ($0.03) earnings per share (EPS) for the quarter. The business had revenue of $1.10 million for the quarter, compared to analysts' expectations of $1.28 million. Sorrento Therapeutics had a negative net margin of 593.94% and a negative return on equity of 84.07%. View Sorrento Therapeutics' Earnings History.
Where is Sorrento Therapeutics' stock going? Where will Sorrento Therapeutics' stock price be in 2017?
5 brokers have issued 1-year price targets for Sorrento Therapeutics' shares. Their forecasts range from $9.00 to $20.00. On average, they expect Sorrento Therapeutics' share price to reach $16.00 in the next twelve months. View Analyst Ratings for Sorrento Therapeutics.
Who are some of Sorrento Therapeutics' key competitors?
Some companies that are related to Sorrento Therapeutics include Rigel Pharmaceuticals (RIGL), Corbus Pharmaceuticals Holdings (CRBP), Immune Design Corp. (IMDZ), GlycoMimetics (GLYC), Minerva Neurosciences (NERV), AVEO Pharmaceuticals (AVEO), DURECT Corporation (DRRX), Ardelyx (ARDX), Oxford BioMedica plc (OXB), Catalyst Pharmaceuticals (CPRX), Akebia Therapeutics (AKBA), Circassia Pharmaceuticals PLC (CIR), Chimerix (CMRX), Pieris Pharmaceuticals (PIRS), Stemline Therapeutics (STML), Clearside Biomedical (CLSD), CymaBay Therapeutics (CBAY) and Cempra (CEMP).
Who are Sorrento Therapeutics' key executives?
Sorrento Therapeutics' management team includes the folowing people:
- William S. Marth, Independent Chairman of the Board
- Henry H. Ji Ph.D., President, Chief Executive Officer, Director
- Kevin Herde, Chief Financial Officer, Executive Vice President
- Mike Royal M.D., Executive Vice President - Clinical and Regulatory Affairs
- Miranda Jayne Toledano, Executive Vice President - Corporate Development
- George Uy, Executive Vice President, Chief Commercial Officer
- David Miao, Chief Technology Officer
- Jaisim Shah, Director
- Yue Wu Ph.D., Director
- David H. Deming, Independent Director
Who owns Sorrento Therapeutics stock?
Sorrento Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Crow Point Partners LLC (0.13%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde, Patrick Soon-Shiong and Yue Alexander Wu. View Institutional Ownership Trends for Sorrento Therapeutics.
Who bought Sorrento Therapeutics stock? Who is buying Sorrento Therapeutics stock?
Sorrento Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Crow Point Partners LLC. Company insiders that have bought Sorrento Therapeutics stock in the last two years include Abg Management Ltd, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde and Yue Alexander Wu. View Insider Buying and Selling for Sorrento Therapeutics.
How do I buy Sorrento Therapeutics stock?
Shares of Sorrento Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sorrento Therapeutics' stock price today?
One share of Sorrento Therapeutics stock can currently be purchased for approximately $2.05.
MarketBeat Community Rating for Sorrento Therapeutics (NASDAQ SRNE)MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Sorrento Therapeutics (NASDAQ:SRNE)Earnings History by Quarter for Sorrento Therapeutics (NASDAQ SRNE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/16/2015 | Q315 | | ($0.03) | $1.28 million | $1.10 million | View | N/A |  |
| 11/4/2014 | Q314 | ($0.32) | ($0.27) | $0.08 million | $1.28 million | View | N/A | |
| 8/6/2014 | | ($0.34) | ($0.33) | $0.08 million | $0.78 million | View | N/A | |
| 5/14/2014 | | ($0.29) | ($0.44) | $0.12 million | $0.98 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Sorrento Therapeutics (NASDAQ:SRNE)2017 EPS Consensus Estimate: ($1.40)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.33) | ($0.33) | ($0.33) |
| Q2 2017 | 1 | ($0.34) | ($0.34) | ($0.34) |
| Q3 2017 | 1 | ($0.35) | ($0.35) | ($0.35) |
| Q4 2017 | 1 | ($0.38) | ($0.38) | ($0.38) |
(Data provided by Zacks Investment Research)
Dividend History for Sorrento Therapeutics (NASDAQ:SRNE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Sorrento Therapeutics (NASDAQ:SRNE)Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 17.51%
Insider Trades by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/15/2017 | Henry Ji | Insider | Buy | 29,001 | $1.81 | $52,491.81 | |
| 6/15/2017 | Jaisim Shah | Director | Buy | 10,002 | $1.79 | $17,903.58 | |
| 4/19/2017 | Abg Management Ltd | Major Shareholder | Buy | 550,000 | $2.00 | $1,100,000.00 | |
| 4/19/2017 | Henry Ji | CEO | Buy | 100,000 | $2.00 | $200,000.00 | |
| 4/13/2017 | Abg Management Ltd | Major Shareholder | Buy | 2,500,000 | $2.00 | $5,000,000.00 | |
| 2/22/2017 | Henry Ji | Insider | Buy | 2,000 | $5.60 | $11,200.00 | |
| 2/10/2017 | Henry Ji | Insider | Buy | 20,000 | $5.15 | $103,000.00 | |
| 2/3/2017 | Jerome B Zeldis | Insider | Buy | 10,000 | $5.15 | $51,500.00 | |
| 2/3/2017 | Kevin Herde | VP | Buy | 3,000 | $5.15 | $15,450.00 | |
| 2/3/2017 | Yue Alexander Wu | Director | Buy | 5,000 | $5.15 | $25,750.00 | |
| 6/29/2016 | Patrick Soon-Shiong | Major Shareholder | Sell | 3,400 | $5.82 | $19,788.00 | |
| 6/23/2016 | Patrick Soon-Shiong | Major Shareholder | Sell | 6,901 | $5.85 | $40,370.85 | |
| 6/15/2016 | Patrick Soon-Shiong | Major Shareholder | Sell | 19,836 | $5.87 | $116,437.32 | |
| 6/14/2016 | Patrick Soon-Shiong | Major Shareholder | Sell | 53,764 | $6.14 | $330,110.96 | |
| 6/13/2016 | Patrick Soon-Shiong | Major Shareholder | Sell | 37,792 | $6.15 | $232,420.80 | |
| 3/7/2016 | Patrick Soon-Shiong | Major Shareholder | Sell | 100,000 | $6.19 | $619,000.00 | |
| 8/26/2015 | Henry Ji | CEO | Buy | 500 | $0.95 | $475.00 | |
| 8/24/2015 | Henry Ji | CEO | Buy | 8,888 | $12.84 | $114,121.92 | |
| 8/21/2015 | Henry Ji | CEO | Buy | 8,888 | $13.08 | $116,255.04 | |
| 11/10/2014 | Henry Ji | CEO | Buy | 5,999 | $4.83 | $28,975.17 | |
| 11/7/2014 | Henry Ji | CEO | Buy | 4,000 | $4.56 | $18,240.00 | |
| 11/6/2014 | Henry Ji | CEO | Buy | 3,000 | $4.53 | $13,590.00 | |
| 12/5/2013 | Henry Ji | CEO | Buy | 1,000 | $8.92 | $8,920.00 | |
| 12/4/2013 | Henry Ji | CEO | Buy | 1,000 | $8.54 | $8,540.00 | |
| 11/25/2013 | Jaisim Shah | Director | Buy | 1,000 | $8.65 | $8,650.00 | |
| 11/22/2013 | Henry Ji | CEO | Buy | 1,000 | $8.47 | $8,470.00 | |
| 11/22/2013 | Opko Health, Inc. | Major Shareholder | Sell | 8,471 | $8.50 | $72,003.50 | |
| 11/21/2013 | George Uy | Insider | Buy | 3,000 | $8.36 | $25,080.00 | |
| 11/21/2013 | Opko Health, Inc. | Major Shareholder | Sell | 4,269 | $8.53 | $36,414.57 | |
| 11/20/2013 | Opko Health, Inc. | Major Shareholder | Sell | 17,062 | $8.75 | $149,292.50 | |
| 11/19/2013 | George Uy | Insider | Buy | 2,031 | $8.61 | $17,486.91 | |
| 11/19/2013 | Henry Ji | CEO | Buy | 2,000 | $8.59 | $17,180.00 | |
| 11/19/2013 | Jaisim Shah | Director | Buy | 1,000 | $9.00 | $9,000.00 | |
| 11/15/2013 | Opko Health, Inc. | Major Shareholder | Sell | 2,710 | $8.75 | $23,712.50 | |
| 11/14/2013 | Opko Health, Inc. | Major Shareholder | Sell | 1,900 | $8.75 | $16,625.00 | |
| 11/13/2013 | Opko Health, Inc. | Major Shareholder | Sell | 13,457 | $8.75 | $117,748.75 | |
| 11/8/2013 | Opko Health, Inc. | Major Shareholder | Sell | 2,000 | $8.75 | $17,500.00 | |
| 11/7/2013 | Opko Health, Inc. | Major Shareholder | Sell | 120,380 | $9.03 | $1,087,031.40 | |
(Data available from 1/1/2013 forward)
Headline Trends for Sorrento Therapeutics (NASDAQ:SRNE)
Latest Headlines for Sorrento Therapeutics (NASDAQ:SRNE)
| Source: |
|
| Date | Headline |
|---|
 | HC Wainwright Analysts Give Sorrento Therapeutics, Inc. (SRNE) a $20.00 Price Target
www.americanbankingnews.com - July 9 at 4:52 PM |
| $4.40 Million in Sales Expected for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) This Quarter
www.americanbankingnews.com - July 2 at 11:02 AM |
 | Sorrento Therapeutics (SRNE) Reports FDA Authorization of IND to Commence Clinical Trial of RTX in Intractable Cancer Pain
www.streetinsider.com - July 1 at 7:48 AM |
 | ETFs with exposure to Sorrento Therapeutics, Inc. : June 30, 2017
finance.yahoo.com - July 1 at 7:48 AM |
| Brokerages Expect Sorrento Therapeutics, Inc. (SRNE) Will Post Earnings of -$0.38 Per Share
www.americanbankingnews.com - June 30 at 11:20 AM |
 | Health Care Sector Update for 06/29/2017: SRNE,OBSV,BLCM - Nasdaq
www.nasdaq.com - June 30 at 6:56 AM |
 | Sorrento Therapeutics Announced FDA Authorization of IND to ... - PR Newswire (press release)
www.prnewswire.com - June 30 at 6:56 AM |
| Sorrento Therapeutics Announced FDA Authorization of IND to Commence Clinical Trial of RTX in Intractable Cancer Pain
finance.yahoo.com - June 30 at 6:56 AM |
| Semnur Pharmaceuticals, Inc., Announces Successful Phase 1 / 2 Trial in Patients with Radicular Pain for Its Lead Product, SP-102
finance.yahoo.com - June 27 at 8:41 AM |
| Sorrento Therapeutics, Inc. (SRNE) Stock Rating Reaffirmed by FBR & Co
www.americanbankingnews.com - June 19 at 12:04 AM |
| ETFs with exposure to Sorrento Therapeutics, Inc. : June 16, 2017
finance.yahoo.com - June 17 at 6:21 AM |
| Sorrento Therapeutics, Inc. (SRNE) Short Interest Update
www.americanbankingnews.com - June 15 at 10:46 PM |
| Sorrento Therapeutics (SRNE) Subsidiary Announces Positive Data from Head to Head Adhesion Study with ZTlido
www.streetinsider.com - June 15 at 9:23 PM |
| Insider Buying: Sorrento Therapeutics, Inc. (SRNE) Insider Acquires 29,001 Shares of Stock
www.americanbankingnews.com - June 15 at 8:06 PM |
| Sorrento Therapeutics, Inc. (SRNE) Director Buys $17,903.58 in Stock
www.americanbankingnews.com - June 15 at 8:06 PM |
| Sorrento Therapeutics Contributes to the Formation of Celularity, Inc. - PR Newswire (press release)
www.prnewswire.com - June 15 at 1:13 AM |
| Sorrento Therapeutics' Pain Subsidiary, SCILEX Pharmaceuticals, Announces Positive Data from Head to Head Adhesion Study with its Lead Product, ZTlido™
finance.yahoo.com - June 15 at 1:13 AM |
| Sorrento Therapeutics Announces Dismissal Of Lawsuits
finance.yahoo.com - June 15 at 1:13 AM |
| Sorrento Therapeutics Contributes to the Formation of Celularity, Inc.
finance.yahoo.com - June 13 at 9:45 AM |
| Technical Insights on Biotech Stocks -- Soligenix, Sorrento Therapeutics, Alcobra, and Akebia Therapeutics - PR Newswire (press release)
www.prnewswire.com - June 9 at 8:49 AM |
| Sorrento Therapeutics Inc (SRNE) Expected to Announce Quarterly Sales of $4.40 Million
www.americanbankingnews.com - June 7 at 8:46 AM |
| Sorrento Therapeutics Inc (SRNE) Expected to Announce Earnings of -$0.38 Per Share
www.americanbankingnews.com - June 5 at 10:08 PM |
| ETFs with exposure to Sorrento Therapeutics, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 10:06 PM |
| Sorrento Therapeutics, Inc. :SRNE-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 3 at 1:35 AM |
| Research Analysts Issue Forecasts for Sorrento Therapeutics Inc's Q3 2017 Earnings (SRNE)
www.americanbankingnews.com - May 24 at 8:08 AM |
| HC Wainwright Reiterates "$20.00" Price Target for Sorrento Therapeutics Inc (SRNE)
www.americanbankingnews.com - May 23 at 8:43 PM |
| Sorrento Therapeutics Inc (SRNE) PT Lowered to $20.00
www.americanbankingnews.com - May 22 at 8:16 AM |
| FBR & Co Trims Sorrento Therapeutics Inc (SRNE) Target Price to $9.00
www.americanbankingnews.com - May 22 at 8:16 AM |
| Sorrento Therapeutics (SRNE) Announces Completion of GMP Manufacturing Plant in Suzhou, China - StreetInsider.com
www.streetinsider.com - May 4 at 8:41 PM |
| Sorrento Therapeutics Announces the Completion of GMP Manufacturing Plant in Suzhou, China to Support its Growing Antibody-Drug Conjugate (ADC) Pipeline and Service Business
finance.yahoo.com - May 4 at 10:51 AM |
| Sorrento Therapeutics (SRNE) Earning Somewhat Positive News Coverage, Report Finds
www.americanbankingnews.com - May 3 at 9:24 PM |
 | Opioid-fighting startup lands CEO, COO with deep pharmaceutical expertise
www.bizjournals.com - May 3 at 6:10 PM |
| ETFs with exposure to Sorrento Therapeutics, Inc. : May 2, 2017
finance.yahoo.com - May 2 at 5:50 PM |
| Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics - PR Newswire (press release)
www.prnewswire.com - April 30 at 3:32 PM |
| Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics - PR Newswire (press release)
www.prnewswire.com - April 30 at 3:32 PM |
| Sorrento Therapeutics (SRNE) Receiving Somewhat Positive Media Coverage, Report Shows
www.americanbankingnews.com - April 29 at 8:28 PM |
| Sorrento Therapeutics Announces Closing of its Acquisition of Virttu ... - Yahoo Finance
finance.yahoo.com - April 29 at 2:15 AM |
| Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
finance.yahoo.com - April 28 at 4:13 PM |
| Sorrento Therapeutics (SRNE) Earning Somewhat Positive News Coverage, Analysis Shows
www.americanbankingnews.com - April 26 at 7:40 PM |
| Sorrento Therapeutics Inc (SRNE) Major Shareholder Purchases $1,100,000.00 in Stock
www.americanbankingnews.com - April 21 at 12:27 PM |
| ETFs with exposure to Sorrento Therapeutics, Inc. : April 20, 2017
finance.yahoo.com - April 20 at 8:06 PM |
| Insider Buying: Sorrento Therapeutics Inc (SRNE) CEO Buys 100,000 Shares of Stock
www.americanbankingnews.com - April 19 at 10:45 PM |
 | Sorrento Therapeutics up 9% as CEO adds to stake
seekingalpha.com - April 19 at 7:58 PM |
| Sorrento Announces Closing of Public Offering of Common Stock
finance.yahoo.com - April 19 at 7:58 PM |
| Somewhat Negative Media Coverage Very Unlikely to Impact Sorrento Therapeutics (SRNE) Stock Price
www.americanbankingnews.com - April 18 at 3:42 PM |
| Insider Buying: Sorrento Therapeutics Inc (SRNE) Major Shareholder Buys 2,500,000 Shares of Stock
www.americanbankingnews.com - April 18 at 8:23 AM |
| Sorrento Therapeutics (SRNE) Prices 23.63M Common Stock Offering at $2/Share - StreetInsider.com
www.streetinsider.com - April 15 at 6:35 PM |
| Sorrento Therapeutics (SRNE) Plans Offering of Common Stock - StreetInsider.com
www.streetinsider.com - April 14 at 3:43 PM |
| Somewhat Negative Press Coverage Somewhat Likely to Impact Sorrento Therapeutics (SRNE) Stock Price
www.americanbankingnews.com - April 14 at 3:26 PM |
| Sorrento Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - April 13 at 7:48 PM |
Sorrento Therapeutics (SRNE) Chart for Thursday, July, 27, 2017
